Inovio Pharmaceuticals Reports Earnings and Beats Analysts' Estimates

Inovio Pharmaceuticals (NASDAQ:INO) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported earnings per share (EPS) of ($0.69), outperforming the analysts’ consensus estimate of ($0.92) by $0.23, according to Zacks.

Stock Performance

On Tuesday, shares of Inovio Pharmaceuticals decreased by 0.5%, closing at $2.10. During the day, the company's stock experienced a trading volume of 595,384 shares, surpassing its average trading volume of 539,758. Currently, Inovio Pharmaceuticals has a market capitalization of $54.81 million and a price-to-earnings (P/E) ratio of -1.00. The stock has a beta of 0.92, indicating relatively lower volatility compared to the market. Over the last 52 weeks, the stock reached a low of $1.74 and a high of $14.75. The 50-day moving average stands at $2.05, while the 200-day moving average is $3.81.

Analyst Ratings and Price Targets

In recent days, several analysts have provided updates concerning Inovio Pharmaceuticals. Oppenheimer revised their price target for the stock from $33.00 to $15.00 while maintaining an "outperform" rating. JMP Securities reiterated a "market outperform" rating, presenting a target price of $18.00. Conversely, HC Wainwright adjusted their price target downward from $5.00 to $3.00 and assigned a "neutral" rating. Among analysts, one has issued a sell rating, two have rated it as hold, and three have given it a buy rating. As reported by MarketBeat.com, the consensus rating for Inovio Pharmaceuticals is "Hold" with an average price target of $12.40.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing DNA medicines for treating and preventing diseases linked to human papillomavirus (HPV), cancer, and various infectious diseases. The company utilizes a DNA medicines platform that includes precisely designed SynCon to identify and optimize the DNA sequence of targeted antigens, along with CELLECTRA smart device technology for effective delivery of DNA plasmids.

Inovio, Earnings, Pharmaceuticals